Keymed Biosciences Inc KEYBF
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- $0.01 / $4,012.92
- Shares Outstanding
- 294.60M
- Market Cap
- —
- Volume/Avg
- 33,500 / 33,500
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,768
- Website
- https://www.keymedbio.com
Valuation
|
Metric
|
KEYBF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KEYBF
|
|---|---|
Quick Ratio | 4.21 |
Current Ratio | 4.83 |
Interest Coverage | 64.80 |
Quick Ratio
KEYBF
Profitability
|
Metric
|
KEYBF
|
|---|---|
Return on Assets (Normalized) | 16.75% |
Return on Equity (Normalized) | 25.38% |
Return on Invested Capital (Normalized) | 19.05% |
Return on Assets
KEYBF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$^vYY@N | LOCK|w#X@ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>R^qt@J | LOCK|N>h% | $83B | |||
| Moderna Inc
MRNA
| LOCK|?!%M%K | LOCK|$? | $81B | |||
| argenx SE ADR
ARGX
| LOCK|?w>wkTp | LOCK|&FR | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|bd<$#Q | LOCK|j!d | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|cJLS%> | LOCK|@B>< | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|vh?zj<# | LOCK|&tZ& | $28B | |||
| Incyte Corp
INCY
| LOCK|<vRPKvY | LOCK|s#C | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|%mpS@X | LOCK|$ZM | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|q>>lWT | LOCK|<v | $14B |
United States